J&J US Pharma Sales Under Pressure From Pricing And Generics
Executive Summary
A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in the second quarter.
You may also be interested in...
Psoriasis Drugs Poised For The Q2 Spotlight
With Celgene's psoriasis pill Otezla for sale and AbbVie in the midst of launching a new competitor to blockbuster brands like Novartis' Cosentyx and J&J's Tremfya, investors will be focused on the category as drug makers report second quarter financials.
Sanofi Myeloma Drug Shines But Darzalex Dominates Still
While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.
J&J Plans 10 Potential Blockbuster Filings By 2023
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.